FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:841-848 March 28, 1996 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

In recent years there has been a series of advances in the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease).^1,2,3,4,5,6 Notwithstanding these advances, our understanding of inflammatory bowel disease⁷ has been hindered by the lack of representative animal models, an absence of pathognomonic features, and inadequate therapeutic end points. Sensitive or specific serologic or genetic markers of inflammatory bowel disease have yet to be identified.⁷ At present, the diagnosis of ulcerative colitis and Crohn's disease and the differentiation between them are based on nonspecific clinical and histologic patterns that are often obscured by intercurrent infectious or iatrogenic events⁸ . . . [Full Text of this Article]

Measurement of Disease Activity

Ulcerative Colitis

Crohn's Disease

Medical Therapy

Corticosteroids

Aminosalicylates

Immunomodulatory Drugs

            Azathioprine and Mercaptopurine

            Cyclosporine

            Methotrexate

Antibiotics

Nutritional Therapies

Supportive Therapy

Future Therapy

Conclusions

Source Information

From the University of Chicago Pritzker School of Medicine, Chicago.

Address reprint requests to Dr. Hanauer at the University of Chicago Medical Center, 5841 S. Maryland Ave., Chicago, Il 60637.

References

This article has been cited by other articles:

• Liu, G., Zhou, J., Fu, Q. S., Wang, J. (2009). The Escherichia coli Azoreductase AzoR Is Involved in Resistance to Thiol-Specific Stress Caused by Electrophilic Quinones. J. Bacteriol. 191: 6394-6400 [Abstract] [Full Text]  
• Chen, H., Xu, H., Kweon, O., Chen, S., Cerniglia, C. E. (2008). Functional role of Trp-105 of Enterococcus faecalis azoreductase (AzoA) as resolved by structural and mutational analysis. Microbiology 154: 2659-2667 [Abstract] [Full Text]  
• Gustot, T, Lemmers, A, Louis, E, Nicaise, C, Quertinmont, E, Belaiche, J, Roland, S, Van Gossum, A, Deviere, J, Franchimont, D (2005). Profile of soluble cytokine receptors in Crohn's disease. Gut 54: 488-495 [Abstract] [Full Text]  
• Bennink, R. J., Peeters, M., Rutgeerts, P., Mortelmans, L. (2004). Evaluation of Early Treatment Response and Predicting the Need for Colectomy in Active Ulcerative Colitis with 99mTc-HMPAO White Blood Cell Scintigraphy. JNM 45: 1698-1704 [Abstract] [Full Text]  
• Clunie, G. P. R., Lennard, L. (2004). Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 43: 13-18 [Abstract] [Full Text]  
• Salh, B., Assi, K., Templeman, V., Parhar, K., Owen, D., Gomez-Munoz, A., Jacobson, K. (2003). Curcumin attenuates DNB-induced murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G235-G243 [Abstract] [Full Text]  
• Radford-Smith, G L, Edwards, J E, Purdie, D M, Pandeya, N, Watson, M, Martin, N G, Green, A, Newman, B, Florin, T H J (2002). Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 51: 808-813 [Abstract] [Full Text]  
• Valentine, J. F. (2001). Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G1044-G1050 [Abstract] [Full Text]  
• Conroy, C A, Cattell, R (2001). Infliximab treatment for Crohn's disease. Postgrad. Med. J. 77: 436-440 [Full Text]  
• Weinshilboum, R. (2001). Thiopurine Pharmacogenetics: Clinical and Molecular Studies of Thiopurine Methyltransferase. Drug Metab. Dispos. 29: 601-605 [Abstract] [Full Text]  
• Cho, J. H., Nicolae, D. L., Ramos, R., Fields, C. T., Rabenau, K., Corradino, S., Brant, S. R., Espinosa, R., LeBeau, M., Hanauer, S. B., Bodzin, J., Bonen, D. K. (2000). Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet 9: 1425-1432 [Abstract] [Full Text]  
• Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., Brubaker, P. L. (2000). Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278: R1057-R1063 [Abstract] [Full Text]  
• Rampton, D. S (1999). Regular review: Management of Crohn's disease. BMJ 319: 1480-1485 [Full Text]  
• PRESENT, D H (1999). Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease?. Gut 44: 592-593 [Full Text]  
• Neurath, M F, Wanitschke, R, Peters, M, Krummenauer, F, zum Buschenfelde, K-H M., Schlaak, J F (1999). Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44: 625-628 [Abstract] [Full Text]  
• Drucker, D. J., Yusta, B., Boushey, R. P., DeForest, L., Brubaker, P. L. (1999). Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 276: G79-G91 [Abstract] [Full Text]  
• Papatheodoridis, G V, Hamilton, M, Mistry, P K, Davidson, B, Rolles, K, Burroughs, A K (1998). Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 43: 639-644 [Abstract] [Full Text]  
• Marteau, P, Crand, J, Foucault, M, Rambaud, J-C (1998). Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 42: 195-199 [Abstract] [Full Text]  
• Autenrieth, I B, Bucheler, N, Bohn, E, Heinze, G, Horak, I (1997). Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation. Gut 41: 793-800 [Abstract] [Full Text]  
• Targan, S. R., Hanauer, S. B., van Deventer, S. J.H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., Rutgeerts, P. J., The Crohn's Disease cA2 Study Group, (1997). A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor {alpha} for Crohn's Disease. NEJM 337: 1029-1036 [Abstract] [Full Text]  
• TZANAKIS, N., SAMIOU, M., BOUROS, D., MOUZAS, J., KOUROUMALIS, E., SIAFAKAS, N. M. (1997). Small Airways Function in Patients with Inflammatory Bowel Disease. Am. J. Respir. Crit. Care Med. 157: 382-386 [Abstract] [Full Text]